Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Employer
- Nature Careers
- Umeå University
- University of Maryland, Baltimore
- Stanford University
- University of Washington
- Baylor College of Medicine
- University of North Carolina at Chapel Hill
- University of Minnesota
- Duke University
- Cornell University
- Harvard University
- The Ohio State University
- University of Oslo
- University of Oxford
- University of Utah
- VIB
- Washington University in St. Louis
- Aarhus University
- FAPESP - São Paulo Research Foundation
- MOHAMMED VI POLYTECHNIC UNIVERSITY
- Massachusetts Institute of Technology
- New York University
- Pennsylvania State University
- Rutgers University
- Stony Brook University
- THE UNIVERSITY OF HONG KONG
- University of Kentucky
- University of Southern Denmark
- University of Virginia
- Wageningen University & Research
- Argonne
- CIML2000
- CNRS
- CRAG-Centre de Recerca Agrigenòmica
- CeMM - Research Center for Molecular Medicine of the Austrian Academy of Sciences
- Central State University
- Delft University of Technology (TU Delft)
- EURECAT
- Foundation for Research and Technology-Hellas
- Gustave Roussy / Inserm
- Heidelberg University
- Indiana University
- Institut Jacques Monod, CNRS UMR 7592
- Institut Pasteur
- KU LEUVEN
- King's College London
- Leibniz
- Max Planck Institute for Multidisciplinary Sciences, Göttingen
- Max Planck Institute of Molecular Cell Biology and Genetics, Dresden
- Medical University of Gdańsk
- National Institute of Chemistry Slovenia
- Purdue University
- RIKEN
- Rice University
- Sanofi
- SciLifeLab
- Technical University of Denmark
- Texas A&M AgriLife
- Texas A&M University
- The University of Arizona
- The University of Western Australia
- UNIVERSITY OF HELSINKI
- Umeå universitet
- Universidade de Coimbra
- Universite de Montpellier
- University of California, Los Angeles
- University of Copenhagen
- University of Dundee;
- University of Glasgow
- University of London
- University of Lund
- University of Luxembourg
- University of Miami
- University of Nebraska Medical Center
- University of Newcastle
- University of Oxford;
- University of Texas at Dallas
- University of Tübingen
- Vrije Universiteit Amsterdam (VU)
- Zintellect
- 70 more »
- « less
-
Field
-
CRISPR genome editing. Duke is an Equal Opportunity Employer committed to providing employment opportunity without regard to an individual's age, color, disability, gender, gender expression, gender
-
University of North Carolina at Chapel Hill | Chapel Hill, North Carolina | United States | 2 months ago
, clarity, chemogenetic and optogenetic manipulation of signaling pathways, CRISPR-Cas9 based genome editing, brain organoids, and single cell sequencing. The lab provides an exceptionally supportive
-
colonies before, during, and after transportation. The candidate should have experience with bee viruses, CRISPR technology, cloning, PCRs, and molecular biology. The postdoctoral scientist is expected
-
pluripotent stem cells (hiPSCs). Primary responsibility is to utilize the CRISPR/Cas9 genomic engineering technology to examine the impact of genomic ablation of the candidate target genes on iPSC-CM and animal
-
identified, the lab explores the biologicacl implications of these biomarkers on CAR T-cell function and develops novel CAR T-cell treatment approaches using cloning, CRISPR-screening, and combinatorial
-
cytometry Extensive experience in cell culture and molecular biology techniques Profound expertise in cell biology and epigenetics Experience in CRISPR/Cas9 genetic engineering, ideally in a high-throughput
-
of these small molecules by identifying their cellular targets using cell biological and biochemical approaches. Second goal is to utilize CRISPR/Cas9 genomic engineering technology to examine the impact of
-
published scientific paper. Experience in the analysis of genomics data and next-generation sequencing library preparations such as RNA-seq, ChIP-Seq, are preferred. Any skills with CRISPR genome engineering
-
using Cre-Lox and AAV-Crispr/Cas9 editing of MP in vivo. The AAV-Crispr/Cas9 approach of editing is in pre-clinical development as a novel therapy for humans with hypertension and heart failure
-
to 1) transiently open the blood brain barrier to improve the delivery of gene-therapy (using customized CRISPR-Cas9 agents) and nano-formulated antiretroviral drugs to the brains of rodent models of HIV